Comparing two rectal cancer surgeries for T2 tumors
Part of Cancer, Digestive system clinical trials.
This trial compares two different surgery approaches for early-stage rectal cancer (T2N0M0) that is close to the anus. It tests whether a less invasive local removal followed by radiation works as well as more extensive surgery (total mesorectal excision).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of rectal cancer called adenocarcinoma, confirmed by a biopsy.
- The tumor is in the lower part of the rectum (within 4 cm of the anus) and is 3 cm or smaller.
- The tumor has not spread to lymph nodes or other parts of the body (stage T2N0M0).
- You have not had prior treatment for rectal cancer, like radiation or chemotherapy.
- You are not pregnant, breastfeeding, or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways of performing rectal cancer surgery: robotic surgery and a newer technique called TaTME (transanal total mesorectal excision). It aims to see which approach has better outcomes for patients. If you're having surgery for rectal cancer, this trial might help you get access to advanced surgical options.
This trial compares a new surgery method that uses multiple technologies to remove rectal cancer more precisely versus the standard surgery. It is for people with middle or lower rectal cancer that hasn't spread, and it may help improve outcomes after surgery.
This trial compares two approaches for low-risk locally advanced rectal cancer: going straight to surgery (TME) versus receiving chemotherapy before surgery. The goal is to see if upfront surgery works just as well, sparing patients from chemotherapy side effects.
This trial looks at whether removing the rectal tumor locally (through the anus) can work as well as a more extensive operation after scans show no remaining cancer. It may help some people avoid bigger surgery if the cancer truly appears gone after treatment.
This trial compares standard chemotherapy to more extensive surgery (total mesorectal excision) for patients whose initial local surgery showed high-risk features like poor differentiation, lymphovascular invasion, or larger tumor size. It aims to find the best treatment to prevent cancer from coming back.
This trial tests whether a full course of chemotherapy and radiation before any surgery (called total neoadjuvant therapy) can help you avoid surgery and preserve your rectum. It is for people with a specific early stage of rectal cancer that has not spread.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.